# Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen

> **NCT00918450** · PHASE2 · WITHDRAWN · sponsor: **Abbott** · enrollment: 150 (estimated)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** ABT-263

## Key facts

- **NCT ID:** NCT00918450
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-03
- **Primary completion:** 2012-12
- **Final completion:** —
- **Target enrollment:** 150 (ESTIMATED)
- **Why stopped:** Sponsor has decided to not proceed with this study.
- **Last updated:** 2010-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00918450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00918450, "Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00918450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*